460 related articles for article (PubMed ID: 19075705)
1. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
2. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
Nagai Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
[TBL] [Abstract][Full Text] [Related]
3. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.
Takeuchi T; Nagai Y
Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29019918
[TBL] [Abstract][Full Text] [Related]
4. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Nagai Y; Fujikake N; Popiel HA; Wada K
Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
[TBL] [Abstract][Full Text] [Related]
6. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
7. A toxic monomeric conformer of the polyglutamine protein.
Nagai Y; Inui T; Popiel HA; Fujikake N; Hasegawa K; Urade Y; Goto Y; Naiki H; Toda T
Nat Struct Mol Biol; 2007 Apr; 14(4):332-40. PubMed ID: 17369839
[TBL] [Abstract][Full Text] [Related]
8. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
Minakawa EN; Nagai Y
Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
[TBL] [Abstract][Full Text] [Related]
9. [Pathomechanism of polyglutamine diseases and strategic design for their therapies].
Nukina N
Rinsho Shinkeigaku; 2008 Nov; 48(11):913-4. PubMed ID: 19198116
[TBL] [Abstract][Full Text] [Related]
10. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
Nagai Y; Nukina N
Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.
Herbst M; Wanker EE
Curr Pharm Des; 2006; 12(20):2543-55. PubMed ID: 16842177
[TBL] [Abstract][Full Text] [Related]
12. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
Kubota H; Kitamura A; Nagata K
Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein.
Scarafone N; Pain C; Fratamico A; Gaspard G; Yilmaz N; Filée P; Galleni M; Matagne A; Dumoulin M
PLoS One; 2012; 7(3):e31253. PubMed ID: 22438863
[TBL] [Abstract][Full Text] [Related]
15. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
[TBL] [Abstract][Full Text] [Related]
16. Conformational diseases: structural studies of aggregation of polyglutamine proteins.
Papaleo E; Invernizzi G
Curr Comput Aided Drug Des; 2011 Mar; 7(1):23-43. PubMed ID: 20807186
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.
Popiel HA; Nagai Y; Onodera O; Inui T; Fujikake N; Urade Y; Strittmatter WJ; Burke JR; Ichikawa A; Toda T
Biochem Biophys Res Commun; 2004 May; 317(4):1200-6. PubMed ID: 15094397
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
Fu L; Gao YS; Sztul E
Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
[TBL] [Abstract][Full Text] [Related]
19. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic strategies for the polyglutamine diseases].
Nagai Y; Popiel HA; Fujikake N; Toda T
Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
